AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16259789 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 100 mg N‐acetylcysteine per day
Number of subjects: 37
Study 16259789 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (ST) based on WHO recommendations
Number of subjects: 37
Study 16259789 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 37
Study 12207629 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI)
Number of subjects: 12
Study 12207629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (NEB)
Number of subjects: 12
Study 12207629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer with 25 g oral charcoal (NEBC)
Number of subjects: 12
Study 12207629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (NEB) vs Nebulizer with charcoal (NEBC)
Number of subjects: 12
Study 12207629 — intervention group
Group type: EXPERIMENTAL
Intervention: Metered Dose Inhaler (MDI) vs Oral (ORAL)
Number of subjects: 12
Study 12207629 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulizer (NEB) vs Oral (ORAL)
Number of subjects: 12
Study 10567754 — intervention group
Group type: EXPERIMENTAL
Intervention: C6 tetraplegia
Number of subjects: 69
Study 10567754 — intervention group
Group type: COMPARATOR
Intervention: Paraplegia
Number of subjects: 69
Study 10567754 — intervention group
Group type: EXPERIMENTAL
Intervention: C7 tetraplegia
Number of subjects: 69
Study 7476326 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 10 mg/d for 12 months
Number of subjects: 18
Study 2341935 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular bone grafts (MBG)
Number of subjects: 40
Study 2341935 — intervention group
Group type: COMPARATOR
Intervention: Iliac crest bone (ICB)
Number of subjects: 40
Study 2341935 — intervention group
Group type: COMPARATOR
Intervention: Both groups (MBG and ICB)
Number of subjects: 40
Study 219269 — intervention group
Group type: EXPERIMENTAL
Intervention: Dianhydrogalactitol plus whole-brain irradiation
Number of subjects: 42
Study 219269 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain irradiation alone
Number of subjects: 42
Study 31813599 — intervention group
Group type: EXPERIMENTAL
Intervention: Instrumentation with rotary files and irrigation with 2.5% sodium hypochlorite (NaOCl) and 17% ethylene diamine tetra acetic acid (EDTA)
Number of subjects: 42
Study 31813599 — intervention group
Group type: COMPARATOR
Intervention: Instrumentation with rotary files and irrigation with sterile saline
Number of subjects: 42
Study 31813599 — intervention group
Group type: COMPARATOR
Intervention: No endodontic intervention
Number of subjects: 42
Study 30522566 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling
Number of subjects: 300
Study 30522566 — intervention group
Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 300
Study 28295198 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 0
Study 25490913 — intervention group
Group type: COMPARATOR
Intervention: Cold pressor test (CPT)
Number of subjects: 93
Study 23890351 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg monacolins
Number of subjects: 25
Study 23890351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 21291335 — intervention group
Group type: EXPERIMENTAL
Intervention: Miglitol (50 mg) before meals
Number of subjects: 10
Study 21291335 — intervention group
Group type: COMPARATOR
Intervention: Acarbose (100 mg) before meals
Number of subjects: 10
Study 19811594 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal Quality Improvement (QI) activities in G1
Number of subjects: 500
Study 19811594 — intervention group
Group type: EXPERIMENTAL
Intervention: External feedback in G2 (subgroup with QI activities)
Number of subjects: 500
Study 19811594 — intervention group
Group type: COMPARATOR
Intervention: Control group G3 (no intervention)
Number of subjects: 500
Study 17120700 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious and unconscious aromatherapy and multimodal sensory activation
Number of subjects: 0
Study 14990595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sputum examination in patients with SARS
Number of subjects: 15
Study 14990595 — intervention group
Group type: COMPARATOR
Intervention: Control samples from age matched controls
Number of subjects: 15
Study 11374092 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral deep brain stimulation (STN stimulation)
Number of subjects: 16
Study 11374092 — intervention group
Group type: COMPARATOR
Intervention: Control group (age-matched controls)
Number of subjects: 16
Study 11374092 — intervention group
Group type: EXPERIMENTAL
Intervention: PD patients off stimulation
Number of subjects: 16
Study 9404766 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg/kg nebulized 2% lidocaine
Number of subjects: 20
Study 9404766 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg nebulized 2% lidocaine
Number of subjects: 20
Study 8175498 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathers (inspired from the loads through a J valve)
Number of subjects: 48
Study 8175498 — intervention group
Group type: EXPERIMENTAL
Intervention: Pullers (reciprocally stroked the plunger of a 2-liter syringe connected to the J valve)
Number of subjects: 48
Study 8175498 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathers with supplemental audio feedback
Number of subjects: 48
Study 8175498 — intervention group
Group type: EXPERIMENTAL
Intervention: Listeners receiving airflow feedback
Number of subjects: 48
Study 3066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothiazide 25 mg
Number of subjects: 132
Study 3066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothiazide 50 mg
Number of subjects: 132
Study 3066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothiazide 100 mg
Number of subjects: 132
Study 3066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxodoline 50 mg
Number of subjects: 132
Study 3066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxodoline 100 mg
Number of subjects: 132
Study 3066965 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothiazide and Oxodoline
Number of subjects: 132
Study 30349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses and The Back Book
Number of subjects: 60
Study 30349585 — intervention group
Group type: COMPARATOR
Intervention: The Back Book
Number of subjects: 60
Study 30349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated foot orthoses
Number of subjects: 60
Study 30349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity
Number of subjects: 60
Study 30349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot type
Number of subjects: 60
Study 30349585 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 60
Study 28222805 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic feedback of step count using an activity tracker wristband
Number of subjects: 120
Study 28222805 — intervention group
Group type: COMPARATOR
Intervention: No automatic feedback
Number of subjects: 120
Study 25618800 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid-piperine combination (1 g curcuminoids + 10 mg piperine daily)
Number of subjects: 117
Study 25618800 — intervention group
Group type: EXPERIMENTAL
Intervention: Curcuminoid-piperine combination
Number of subjects: 117
Study 25618800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 24335016 — intervention group
Group type: EXPERIMENTAL
Intervention: SAL plus RFAL
Number of subjects: 12
Study 24335016 — intervention group
Group type: COMPARATOR
Intervention: SAL alone
Number of subjects: 12
Study 20513160 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD 15% solution (Psorent)
Number of subjects: 60
Study 20513160 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriene 0.005% cream (Dovonex)
Number of subjects: 60
Study 18226128 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic saline solution infusion (EASI) plus dexamethasone 20 mg
Number of subjects: 84
Study 18226128 — intervention group
Group type: COMPARATOR
Intervention: Extra-amniotic saline solution infusion (EASI) alone
Number of subjects: 84
Study 18226128 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone plus EASI
Number of subjects: 84
Study 18226128 — intervention group
Group type: COMPARATOR
Intervention: EASI alone
Number of subjects: 84
Study 18226128 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 84
Study 16967629 — intervention group
Group type: EXPERIMENTAL
Intervention: E2/norgestimate (NGM) 1 mg/90 microg
Number of subjects: 67
Study 16967629 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed E2 1 mg
Number of subjects: 67
Study 12837670 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 1 mg/day
Number of subjects: 0
Study 12837670 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone 2 mg/day
Number of subjects: 0
Study 12837670 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10989586 — intervention group
Group type: EXPERIMENTAL
Intervention: Coltosol
Number of subjects: 100
Study 10989586 — intervention group
Group type: EXPERIMENTAL
Intervention: Algenol
Number of subjects: 100
Study 10989586 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 100
Study 10989586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermit
Number of subjects: 100
Study 10989586 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermit-N
Number of subjects: 100
Study 9011450 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (200 mg)
Number of subjects: 6
Study 9011450 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 1334255 — intervention group
Group type: EXPERIMENTAL
Intervention: Live oral tetravalent human‐rhesus rotavirus reassortant vaccine
Number of subjects: 240
Study 1334255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 6519213 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythrapheresis
Number of subjects: 10
Study 6519213 — intervention group
Group type: COMPARATOR
Intervention: Placebo apheresis
Number of subjects: 10
Study 31131360 — intervention group
Group type: COMPARATOR
Intervention: Open surgery (OP)
Number of subjects: 1057
Study 31131360 — intervention group
Group type: EXPERIMENTAL
Intervention: Operation time >240 minutes
Number of subjects: 1057
Study 31131360 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound complication
Number of subjects: 1057
Study 29321218 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous saline administration
Number of subjects: 27
Study 29321218 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary salt modification
Number of subjects: 27
Study 29321218 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-II stimulation testing
Number of subjects: 27
Study 26707353 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised exercise training
Number of subjects: 30
Study 25298578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine 10 mg once daily for 8 weeks
Number of subjects: 122
Study 25298578 — intervention group
Group type: COMPARATOR
Intervention: Pantoprazole 40 mg once daily for 8 weeks
Number of subjects: 122
Study 25298578 — intervention group
Group type: EXPERIMENTAL
Intervention: Lafutidine and Pantoprazole
Number of subjects: 122
Study 22789793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 90
Study 22789793 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 90
Study 22789793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 20302004 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 100
Study 20302004 — intervention group
Group type: COMPARATOR
Intervention: Budesonide 256 microg
Number of subjects: 100
Study 17958990 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Bronchitis Severity Score (ABSS)
Number of subjects: 649
Study 15127186 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% hydroxyethyl starch (HES)
Number of subjects: 30
Study 15127186 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% modified fluid gelatine (GEL)
Number of subjects: 30
Study 15127186 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 30
Study 11899903 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL172 with chemotherapy (n=14)
Number of subjects: 28
Study 11899903 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (n=14)
Number of subjects: 28
Study 11899903 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment regimens (SRL172 + chemotherapy and chemotherapy alone)
Number of subjects: 28
Study 11899903 — intervention group
Group type: EXPERIMENTAL
Intervention: SRL172 with chemotherapy
Number of subjects: 28
Study 9437338 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver
Number of subjects: 148
Study 9437338 — intervention group
Group type: COMPARATOR
Intervention: Carotid sinus massage (CSM)
Number of subjects: 148
Study 9437338 — intervention group
Group type: COMPARATOR
Intervention: Carotid sinus massage (CSM) after Valsalva maneuver
Number of subjects: 148
Study 9437338 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva maneuver after CSM
Number of subjects: 148
Study 9437338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined Valsalva maneuver and CSM
Number of subjects: 148
Study 8073455 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancrod
Number of subjects: 132
Study 8073455 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 2678635 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (VP) therapy prior to administration of CsA
Number of subjects: 40
Study 2678635 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (VP) therapy
Number of subjects: 40
Study 2678635 — intervention group
Group type: COMPARATOR
Intervention: No drug (control)
Number of subjects: 40
Study 31479196 — intervention group
Group type: EXPERIMENTAL
Intervention: Myjet-assisted transdermal injection of tranexamic acid (TA)
Number of subjects: 17
Study 31479196 — intervention group
Group type: EXPERIMENTAL
Intervention: Myjet-assisted transdermal injection of vitamin C (VC)
Number of subjects: 17
Study 31479196 — intervention group
Group type: COMPARATOR
Intervention: Comparison between TA and VC
Number of subjects: 17
Study 28918682 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom training
Number of subjects: 50
Study 28918682 — intervention group
Group type: EXPERIMENTAL
Intervention: Classroom training coupled with smartphone app training
Number of subjects: 50
Study 28918682 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer training
Number of subjects: 50
Study 28918682 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional face‐to‐face training)
Number of subjects: 50
Study 28092488 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Level Laser Therapy (LLLT)
Number of subjects: 40
Study 28092488 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 26301771 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 3 mg
Number of subjects: 627
Study 26301771 — intervention group
Group type: EXPERIMENTAL
Intervention: brexpiprazole 1 mg
Number of subjects: 627
Study 26301771 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 627
Study 23735680 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN1Δ30 at 10PFU and 1000PFU doses
Number of subjects: 0
Study 23735680 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN2/4Δ30 at 10PFU and 1000PFU doses
Number of subjects: 0
Study 23735680 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN3Δ30/31 at 10PFU and 1000PFU doses
Number of subjects: 0
Study 23735680 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN1Δ30 at 1000PFU and 10PFU doses
Number of subjects: 0
Study 23735680 — intervention group
Group type: EXPERIMENTAL
Intervention: DEN2/4Δ30 and DEN3Δ30/31
Number of subjects: 0
Study 21183518 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral lidocaine 1% (0.5 cc)
Number of subjects: 506
Study 21183518 — intervention group
Group type: COMPARATOR
Intervention: Balanced salt solution (BSS)
Number of subjects: 506
Study 19877967 — intervention group
Group type: EXPERIMENTAL
Intervention: Benznidazole (5 mg/kg per day for 30 days)
Number of subjects: 0
Study 19877967 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 0
Study 16828480 — intervention group
Group type: EXPERIMENTAL
Intervention: Inherited thrombophilia
Number of subjects: 41
Study 16828480 — intervention group
Group type: COMPARATOR
Intervention: Women without inherited thrombophilia
Number of subjects: 41
Study 12956652 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine spray applied twice daily
Number of subjects: 13
Study 12956652 — intervention group
Group type: COMPARATOR
Intervention: 0.2% chlorhexidine spray applied once daily plus placebo spray once daily
Number of subjects: 13
Study 11076106 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. calcitriol plus calcium carbonate (CaCO3)
Number of subjects: 0
Study 11076106 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CaCO3) alone (control)
Number of subjects: 0
Study 8717610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary selenium at 356 micrograms/day
Number of subjects: 11
Study 8717610 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary selenium at 13 micrograms/day
Number of subjects: 11
Study 8717610 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-selenium group (13 micrograms/day)
Number of subjects: 11
Study 8717610 — intervention group
Group type: EXPERIMENTAL
Intervention: Typical U.S. diet with selenium supplementation
Number of subjects: 11
Study 1559584 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg (150 mg if B.W. < 40 kg) as a single evening dose for four weeks
Number of subjects: 37
Study 1559584 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine
Number of subjects: 37
Study 4042527 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol
Number of subjects: 0
Study 4042527 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 4042527 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline
Number of subjects: 0
Study 4042527 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevantolol with terbutaline
Number of subjects: 0
Study 4042527 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30932313 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged-release tacrolimus (PR-T)
Number of subjects: 74
Study 30932313 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release tacrolimus (IR-T)
Number of subjects: 74
Study 29280806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal connected care model with RNs
Number of subjects: 41
Study 29280806 — intervention group
Group type: COMPARATOR
Intervention: Traditional care model (implied control)
Number of subjects: 41
Study 27769295 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP-based gestational age assessment
Number of subjects: 353
Study 27769295 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP-based classification of preterm birth
Number of subjects: 353
Study 27769295 — intervention group
Group type: EXPERIMENTAL
Intervention: LMP-based classification of post-term birth
Number of subjects: 353
Study 25151658 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone nasal spray for six months
Number of subjects: 62
Study 25151658 — intervention group
Group type: COMPARATOR
Intervention: Saline nasal spray for six months
Number of subjects: 62
Study 22370297 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 0
Study 22370297 — intervention group
Group type: COMPARATOR
Intervention: Alendronate
Number of subjects: 0
Study 20034816 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with abnormal D-dimer who did not resume anticoagulation
Number of subjects: 490
Study 20034816 — intervention group
Group type: COMPARATOR
Intervention: Patients with normal D-dimer
Number of subjects: 490
Study 20034816 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with RVO
Number of subjects: 490
Study 20034816 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without RVO
Number of subjects: 490
Study 19851798 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated linoleic acid (CLA) isomers (3.9 g per day, 50:50 t9c11:c10t12)
Number of subjects: 25
Study 19851798 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high-oleic-acid sunflower oil, 3.9 g per day)
Number of subjects: 25
Study 16106138 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 0
Study 16106138 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 0
Study 16106138 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 0
Study 12384357 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem (INVANZ) at doses up to 3 g
Number of subjects: 0
Study 10103305 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF (10 microg/kg/d) by subcutaneous injection for 5 days
Number of subjects: 75
Study 10103305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no GM‐CSF treatment)
Number of subjects: 75
Study 10103305 — intervention group
Group type: EXPERIMENTAL
Intervention: GM‐CSF
Number of subjects: 75
Study 7577779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl added to mepivacaine (75 micrograms with 30 mL mepivacaine 1.5% with epinephrine 5 micrograms/mL)
Number of subjects: 20
Study 7577779 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 20
Study 7577779 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl added to mepivacaine
Number of subjects: 20
Study 2260333 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen
Number of subjects: 28
Study 2260333 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 28
Study 2260333 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 2260333 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen and Sulindac
Number of subjects: 28
Study 7219899 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity exercise programme
Number of subjects: 0
Study 7219899 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity exercise programme
Number of subjects: 0